Upadacitinib in Crohn's disease: real-world experience

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Small molecule therapies represent a growing treatment option for inflammatory bowel disease.
• Upadacitinib, a Janus kinase (JAK) inhibitor, has recently gained approval for Crohn's disease treatment.
• While clinical trials show impressive efficacy, real-world data is limited.

Purpose of the Study:

• To consolidate and summarize existing real-world evidence on upadacitinib in Crohn's disease.
• To provide a comprehensive overview of upadacitinib's performance in routine clinical settings.
• To identify trends and outcomes from diverse patient populations treated with upadacitinib.

Main Methods:

• Systematic literature search for studies reporting real-world data on upadacitinib in Crohn's disease.
• Inclusion of observational studies, case series, and registries.
• Data extraction focusing on efficacy, safety, and patient-reported outcomes.

Main Results:

• Real-world data indicates consistent efficacy of upadacitinib in achieving clinical remission and endoscopic improvement in Crohn's disease patients.
• Safety profile in real-world settings aligns with clinical trial findings, with manageable adverse events.
• Variability in treatment response observed across different patient subgroups.

Conclusions:

• Upadacitinib demonstrates promising real-world effectiveness and a manageable safety profile for Crohn's disease management.
• Further research is needed to optimize its use in specific patient phenotypes and long-term outcomes.
• Real-world data is crucial for understanding the broader clinical utility of upadacitinib in inflammatory bowel disease.